扩大临床应用生物反应器制造人间充质干细胞

IF 3.2 4区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Current Research in Translational Medicine Pub Date : 2023-04-01 DOI:10.1016/j.retram.2023.103393
Marina Gazdic Jankovic , Miodrag Stojkovic , Sanja Bojic , Nemanja Jovicic , Marina Miletic Kovacevic , Zeljko Ivosevic , Aleksandar Juskovic , Vojin Kovacevic , Biljana Ljujic
{"title":"扩大临床应用生物反应器制造人间充质干细胞","authors":"Marina Gazdic Jankovic ,&nbsp;Miodrag Stojkovic ,&nbsp;Sanja Bojic ,&nbsp;Nemanja Jovicic ,&nbsp;Marina Miletic Kovacevic ,&nbsp;Zeljko Ivosevic ,&nbsp;Aleksandar Juskovic ,&nbsp;Vojin Kovacevic ,&nbsp;Biljana Ljujic","doi":"10.1016/j.retram.2023.103393","DOIUrl":null,"url":null,"abstract":"<div><p>Human mesenchymal stem cells (hMSCs) are multipotent cells and an attractive therapeutic agent in regenerative medicine and intensive clinical research. Despite the great potential, the limitation that needs to be overcome is the necessity of <em>ex vivo</em> expansion because of insufficient number of hMSCs presented within adult organs and the high doses required for a transplantation. As a result, numerous research studies aim to provide novel expansion methods in order to achieve appropriate numbers of cells with preserved therapeutic quality. Bioreactor-based cell expansion provide high-level production of hMSCs in accordance with good manufacturing practice (GMP) and quality standards. This review summarizes current knowledge about the hMSCs manufacturing platforms with a main focus to the application of bioreactors for large-scale production of GMP-grade hMSCs.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 2","pages":"Article 103393"},"PeriodicalIF":3.2000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Scaling up human mesenchymal stem cell manufacturing using bioreactors for clinical uses\",\"authors\":\"Marina Gazdic Jankovic ,&nbsp;Miodrag Stojkovic ,&nbsp;Sanja Bojic ,&nbsp;Nemanja Jovicic ,&nbsp;Marina Miletic Kovacevic ,&nbsp;Zeljko Ivosevic ,&nbsp;Aleksandar Juskovic ,&nbsp;Vojin Kovacevic ,&nbsp;Biljana Ljujic\",\"doi\":\"10.1016/j.retram.2023.103393\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Human mesenchymal stem cells (hMSCs) are multipotent cells and an attractive therapeutic agent in regenerative medicine and intensive clinical research. Despite the great potential, the limitation that needs to be overcome is the necessity of <em>ex vivo</em> expansion because of insufficient number of hMSCs presented within adult organs and the high doses required for a transplantation. As a result, numerous research studies aim to provide novel expansion methods in order to achieve appropriate numbers of cells with preserved therapeutic quality. Bioreactor-based cell expansion provide high-level production of hMSCs in accordance with good manufacturing practice (GMP) and quality standards. This review summarizes current knowledge about the hMSCs manufacturing platforms with a main focus to the application of bioreactors for large-scale production of GMP-grade hMSCs.</p></div>\",\"PeriodicalId\":54260,\"journal\":{\"name\":\"Current Research in Translational Medicine\",\"volume\":\"71 2\",\"pages\":\"Article 103393\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Research in Translational Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S245231862300017X\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S245231862300017X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 1

摘要

人间充质干细胞(hMSCs)是一种多能细胞,在再生医学和深入临床研究中是一种有吸引力的治疗剂。尽管潜力巨大,但需要克服的限制是离体扩增的必要性,因为成人器官中存在的hMSCs数量不足,移植所需的剂量也很高。因此,许多研究旨在提供新的扩增方法,以获得适当数量的细胞并保持治疗质量。基于生物反应器的细胞扩增根据良好生产规范(GMP)和质量标准提供高水平的hMSC生产。这篇综述总结了目前关于hMSCs生产平台的知识,主要关注生物反应器在大规模生产GMP级hMSCs中的应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Scaling up human mesenchymal stem cell manufacturing using bioreactors for clinical uses

Human mesenchymal stem cells (hMSCs) are multipotent cells and an attractive therapeutic agent in regenerative medicine and intensive clinical research. Despite the great potential, the limitation that needs to be overcome is the necessity of ex vivo expansion because of insufficient number of hMSCs presented within adult organs and the high doses required for a transplantation. As a result, numerous research studies aim to provide novel expansion methods in order to achieve appropriate numbers of cells with preserved therapeutic quality. Bioreactor-based cell expansion provide high-level production of hMSCs in accordance with good manufacturing practice (GMP) and quality standards. This review summarizes current knowledge about the hMSCs manufacturing platforms with a main focus to the application of bioreactors for large-scale production of GMP-grade hMSCs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Research in Translational Medicine
Current Research in Translational Medicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology
CiteScore
7.00
自引率
4.90%
发文量
51
审稿时长
45 days
期刊介绍: Current Research in Translational Medicine is a peer-reviewed journal, publishing worldwide clinical and basic research in the field of hematology, immunology, infectiology, hematopoietic cell transplantation, and cellular and gene therapy. The journal considers for publication English-language editorials, original articles, reviews, and short reports including case-reports. Contributions are intended to draw attention to experimental medicine and translational research. Current Research in Translational Medicine periodically publishes thematic issues and is indexed in all major international databases (2017 Impact Factor is 1.9). Core areas covered in Current Research in Translational Medicine are: Hematology, Immunology, Infectiology, Hematopoietic, Cell Transplantation, Cellular and Gene Therapy.
期刊最新文献
Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations. Identifying potential prognosis markers in relapsed multiple myeloma via integrated bioinformatics analysis and biological experiments. Advances in the relationship of immune checkpoint inhibitors and DNA damage repair. The impact of artificial intelligence and machine learning in organ retrieval and transplantation: A comprehensive review. Construction of a stromal-related prognostic model in acute myeloid leukemia by comprehensive bioinformatics analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1